## Isabella Kardys

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3408587/publications.pdf

Version: 2024-02-01

186265 206112 2,847 135 28 48 citations h-index g-index papers 136 136 136 4979 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Aortic dilation and growth in women with Turner syndrome. Heart, 2023, 109, 102-110.	2.9	7
2	Impact of Baseline and Newly Acquired Conduction Disorders on Need for Permanent Pacemakers With 3 Consecutive Generations of Self-Expanding Transcatheter Aortic Heart Valves. Cardiovascular Revascularization Medicine, 2022, 34, 40-45.	0.8	4
3	Relative conditional survival analysis provides additional insights into the prognosis of heart failure patients. European Journal of Preventive Cardiology, 2022, 29, e72-e73.	1.8	O
4	Clinical consequences of consecutive self-expanding transcatheter heart valve iterations. Netherlands Heart Journal, 2022, 30, 140-148.	0.8	2
5	Transcatheter Edge-to-Edge Repair in Proportionate Versus Disproportionate Functional Mitral Regurgitation. Journal of the American Society of Echocardiography, 2022, 35, 105-115.e8.	2.8	13
6	Endovascular renal sympathetic denervation to improve heart failure with reduced ejection fraction: the IMPROVE-HF-I study. Netherlands Heart Journal, 2022, 30, 149-159.	0.8	4
7	Variability in lipid measurements can have major impact on treatment during secondary prevention. European Journal of Preventive Cardiology, 2022, 28, e4-e5.	1.8	O
8	Cardiovascular Biomarker Profiles in Obesity and Relation to Normalization of Subclinical Cardiac Dysfunction after Bariatric Surgery. Cells, 2022, 11, 422.	4.1	4
9	Relation of Iron Status to Prognosis After Acute Coronary Syndrome. American Journal of Cardiology, 2022, 168, 22-30.	1.6	6
10	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers, 2022, 27, 264-269.	1.9	3
11	Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). Scientific Reports, 2022, 12, 2795.	3.3	9
12	Diagnostic Accuracy of Coronary Angiography-Based Vessel Fractional Flow Reserve (vFFR) Virtual Stenting. Journal of Clinical Medicine, 2022, 11, 1397.	2.4	4
13	Effect of next generation pulsatile mechanical circulatory support on cardiac mechanics - The PULSE trial. Cardiovascular Revascularization Medicine, 2022, , .	0.8	O
14	Prognostic value of post-percutaneous coronary intervention diastolic pressure ratio. Netherlands Heart Journal, 2022, , $1. $	0.8	1
15	Comparison of diagnostic accuracy measures of novel 3D quantitative coronary angiography based software and diastolic pressure ratio for fractional flow Reserve. A single center pooled analysis of FAST EXTEND and FAST II studies. IJC Heart and Vasculature, 2022, 39, 100986.	1.1	1
16	Prognostic value of left atrial strain in patients with congenital aortic stenosis. European Heart Journal Open, 2022, 2, .	2.3	8
17	Three-dimensional QCA-based vessel fractional flow reserve (vFFR) in Heart Team decision-making: a multicentre, retrospective, cohort study. BMJ Open, 2022, 12, e054202.	1.9	2
18	Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study. Open Heart, 2022, 9, e001955.	2.3	4

#	Article	IF	CITATIONS
19	Near-infrared spectroscopy to predict plaque progression in plaque-free artery regions. EuroIntervention, 2022, 18, 253-261.	3.2	4
20	Coronary lithotripsy for the treatment of underexpanded stents: the international multicentre CRUNCH registry. EuroIntervention, 2022, 18, 574-581.	3.2	28
21	Long-term follow-up of patients undergoing renal sympathetic denervation. Clinical Research in Cardiology, 2022, 111, 1256-1268.	3.3	7
22	Impact of membranous septum length on pacemaker need with different transcatheter aortic valve replacement systems: The INTERSECT registry. Journal of Cardiovascular Computed Tomography, 2022, 16, 524-530.	1.3	17
23	Correlation between 3Dâ€QCA based FFR and quantitative lumen assessment by IVUS for left main coronary artery stenoses. Catheterization and Cardiovascular Interventions, 2021, 97, E495-E501.	1.7	11
24	Pairwise estimation of multivariate longitudinal outcomes in a Bayesian setting with extensions to the joint model. Statistical Modelling, 2021, 21, 115-136.	1.1	2
25	Improvement of late gadolinium enhancement image quality using a deep learning–based reconstruction algorithm and its influence on myocardial scar quantification. European Radiology, 2021, 31, 3846-3855.	4.5	31
26	Personalized screening intervals for kidney function in patients with chronic heart failure: a modeling study. Journal of Nephrology, 2021, 34, 1421-1427.	2.0	1
27	Real-time handling of missing predictors. European Heart Journal Digital Health, 2021, 2, 152-153.	1.7	0
28	Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomarkers in Medicine, 2021, 15, 247-255.	1.4	2
29	The legacy of HOPE-3. European Heart Journal, 2021, 42, 3008-3010.	2.2	2
30	Impact of Interventricular membranous septum length on pacemaker need with different Transcatheter aortic valve implantation systems. International Journal of Cardiology, 2021, 333, 152-158.	1.7	13
31	Sex-specific temporal evolution of circulating biomarkers in patients with chronic heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 334, 126-134.	1.7	6
32	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	3.1	11
33	Biomarker profiles in obesity patients and their relation to cardiac dysfunction. Biomarkers in Medicine, 2021, 15, 1211-1221.	1.4	2
34	Personalized screening intervals for measurement of N-terminal pro-B-type natriuretic peptide improve efficiency of prognostication in patients with chronic heart failure. European Journal of Preventive Cardiology, 2021, 28, e11-e14.	1.8	4
35	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. Diabetes and Vascular Disease Research, 2021, 18, 147916412110474.	2.0	1
36	Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors. JACC: CardioOncology, 2021, 3, 695-706.	4.0	11

#	Article	IF	Citations
37	Renal sympathetic denervation in patients with vasospastic angina. Journal of Nuclear Cardiology, 2020, 27, 2202-2209.	2.1	3
38	Growth of the thoracic aorta in the smoking population: The Danish Lung Cancer Screening Trial. International Journal of Cardiology, 2020, 299, 276-281.	1.7	7
39	Evolution of renal function and predictive value of serial renal assessments among patients with acute coronary syndrome: BIOMArCS study. International Journal of Cardiology, 2020, 299, 12-19.	1.7	3
40	Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients. European Heart Journal Cardiovascular Imaging, 2020, 21, 1005-1012.	1,2	7
41	Vascular Complications after Transfemoral Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis. Structural Heart, 2020, 4, 62-71.	0.6	3
42	The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis. Transplantation, 2020, 104, 1508-1518.	1.0	16
43	P1825 Myocardial bridging and coronary artery disease in hypertrophic cardiomyopathy: a matched case control study. European Heart Journal Cardiovascular Imaging, 2020, 21, .	1.2	0
44	Effect of renal denervation on catecholamines and the renin–angiotensin–aldosterone system. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032094309.	1.7	9
45	Young@Heart: empowering the next generation of cardiovascular researchers. Netherlands Heart Journal, 2020, 28, 25-30.	0.8	1
46	Serially Measured Cytokines and Cytokine Receptors in Relation to Clinical Outcome in Patients With Stable Heart Failure. Canadian Journal of Cardiology, 2020, 36, 1587-1591.	1.7	2
47	Contact feedback improves 1-year outcomes of remote magnetic navigation-guided ischemic ventricular tachycardia ablation. International Journal of Cardiology, 2020, 315, 36-44.	1.7	8
48	Joint models with multiple longitudinal outcomes and a time-to-event outcome: a corrected two-stage approach. Statistics and Computing, 2020, 30, 999-1014.	1.5	24
49	Temporal patterns of macrophage―and neutrophil―elated markers are associated with clinical outcome in heart failure patients. ESC Heart Failure, 2020, 7, 1190-1200.	3.1	17
50	Impact of machine-learning CT-derived fractional flow reserve for the diagnosis and management of coronary artery disease in the randomized CRESCENT trials. European Radiology, 2020, 30, 3692-3701.	4.5	15
51	Optimized electrocardiographic criteria for the detection of left ventricular hypertrophy in obesity patients. Clinical Cardiology, 2020, 43, 483-490.	1.8	10
52	Frequency and Significance of Coronary Artery Disease and Myocardial Bridging in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2020, 125, 1404-1412.	1.6	19
53	Predictors for Clinical Outcome of Untreated Stent Edge Dissections as Detected by Optical Coherence Tomography. Circulation: Cardiovascular Interventions, 2020, 13, e008685.	3.9	12
54	Incidence of endâ€stage renal disease after heart transplantation and effect of its treatment on survival. ESC Heart Failure, 2020, 7, 533-541.	3.1	29

#	Article	IF	Citations
55	A valueâ€based healthcare approach: Healthâ€related quality of life and psychosocial functioning in women with Turner syndrome. Clinical Endocrinology, 2020, 92, 434-442.	2.4	20
56	Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bioâ€SHiFT study). Clinical Cardiology, 2020, 43, 630-638.	1.8	9
57	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
58	Serially measured cytokines and cytokine receptors in relation to clinical outcome in patients with stable heart failure. European Heart Journal, 2020, 41, .	2.2	0
59	Intermodality variation of aortic dimensions: How, where and when to measure the ascending aorta. International Journal of Cardiology, 2019, 276, 230-235.	1.7	31
60	Utility of temporal profiles of new cardio-renal and pulmonary candidate biomarkers in chronic heart failure. International Journal of Cardiology, 2019, 276, 157-165.	1.7	22
61	Myocardial Injury Post Transcatheter Aortic Valve Implantation Comparing Mechanically Expanded Versus Self-Expandable Versus Balloon-Expandable Valves. Structural Heart, 2019, 3, 431-437.	0.6	3
62	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. Journal of the American Society of Echocardiography, 2019, 32, 1000-1009.	2.8	7
63	Anti-Oxidized LDL Antibodies and Coronary Artery Disease: A Systematic Review. Antioxidants, 2019, 8, 484.	5.1	35
64	P1640Longitudinal patterns of NT-proBNP, troponin T and CRP in relation to the dynamics of echocardiographic parameters in heart failure patients. European Heart Journal, 2019, 40, .	2.2	0
65	Response: Serial blood biomarker measurements for elucidation of the pathophysiology of heart failure. International Journal of Cardiology, 2019, 278, 266.	1.7	0
66	Response to Letter to the Editor: "Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study)― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 736-737.	3.6	1
67	Understanding of interaction (subgroup) analysis in clinical trials. European Journal of Clinical Investigation, 2019, 49, e13145.	3.4	50
68	Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission. American Heart Journal, 2019, 216, 143-146.	2.7	3
69	5948Circulating biomarkers of cell adhesion in relation to clinical outcomes in patients with chronic heart failure: the Bio-SHiFT study. European Heart Journal, 2019, 40, .	2.2	0
70	P1644Personalized screening intervals for measurement of n-terminal pro-b-type natriuretic peptide improve efficiency of prognostication in patients with chronic heart failure. European Heart Journal, 2019, 40, .	2.2	0
71	Evaluation of atrial septal defects with 4D flow MRIâ€"multilevel and inter-reader reproducibility for quantification of shunt severity. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2019, 32, 269-279.	2.0	34
72	Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study. Clinical Research in Cardiology, 2019, 108, 634-642.	3.3	38

#	Article	lF	Citations
73	The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients. Biomarkers, 2019, 24, 199-205.	1.9	5
74	Genetics, Clinical Features, and Long-TermÂOutcome of NoncompactionÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 711-722.	2.8	242
75	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. American Heart Journal, 2018, 196, 36-48.	2.7	40
76	Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. European Heart Journal, 2018, 39, 295-302.	2.2	96
77	Development and validation of a risk model for longâ€term mortality after percutaneous coronary intervention: The IDEAâ€BIO Study. Catheterization and Cardiovascular Interventions, 2018, 91, 686-695.	1.7	3
78	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. European Journal of Heart Failure, 2018, 20, 89-96.	7.1	48
79	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney International, 2018, 93, 952-960.	5.2	26
80	Realâ€Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. Clinical Pharmacology and Therapeutics, 2018, 104, 346-355.	4.7	2
81	P2724Washout and long-term stabilization of cholesterols after acute coronary syndrome. European Heart Journal, 2018, 39, .	2.2	0
82	P4198The predictive value of Pd/pa and resting diastolic pressure ratio (DPR) on 1-year adverse cardiovascular event following contemporary percutaneous coronary intervention. European Heart Journal, 2018, 39, .	2.2	0
83	P1558The time course of immuno- and inflammo-proteomics prior to a recurrent coronary event in post-acute coronary syndrome patients. European Heart Journal, 2018, 39, .	2.2	0
84	P5665Coagulation biomarkers and clinical outcomes in patients with chronic heart failure - The bio-shift study. European Heart Journal, 2018, 39, .	2.2	0
85	e-Transmission of ECGs for expert consultation results in improved triage and treatment of patients with acute ischaemic chest pain by ambulance paramedics. Netherlands Heart Journal, 2018, 26, 562-571.	0.8	9
86	Validation of Resting Diastolic Pressure Ratio Calculated by a Novel Algorithm and Its Correlation With Distal Coronary Artery Pressure to Aortic Pressure, Instantaneous Wave–Free Ratio, and Fractional Flow Reserve. Circulation: Cardiovascular Interventions, 2018, 11, e006911.	3.9	39
87	P6245High frequency metabolite profiling and the incidence of recurrent coronary events in post-acute coronary syndrome patients. European Heart Journal, 2018, 39, .	2.2	0
88	Prognostic Value of IntravascularÂUltrasound in PatientsÂWithÂCoronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 2003-2011.	2.8	38
89	Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy). Current Atherosclerosis Reports, 2018, 20, 52.	4.8	9
90	Effect of Gender and Genetic Mutations on Outcomes in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1947-1954.	1.6	27

#	Article	IF	CITATIONS
91	IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). EBioMedicine, 2018, 36, 63-72.	6.1	22
92	Personalized dynamic risk assessment in nephrology is a next step in prognostic research. Kidney International, 2018, 94, 214-217.	5.2	17
93	Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of Lipid Research, 2018, 59, 1729-1737.	4.2	105
94	SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease. PLoS ONE, 2018, 13, e0200076.	2.5	9
95	Addition of routinely measured blood biomarkers significantly improves GRACE risk stratification in patients with myocardial infarction. International Journal of Cardiology, 2018, 273, 237-242.	1.7	15
96	Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study). Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3954-3964.	3.6	27
97	Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. Arquivos Brasileiros De Cardiologia, 2018, 111, 345-353.	0.8	3
98	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. International Journal of Cardiology, 2017, 235, 124-132.	1.7	36
99	Impact of Relative Conditional Survival Estimates on Patient Prognosis After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	6
100	Current MitraClip experience, safety and feasibility in the Netherlands. Netherlands Heart Journal, 2017, 25, 394-400.	0.8	10
101	Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2017, 120, 2221-2225.	1.6	16
102	P660Associations of 26 circulating inflammatory and renal biomarkers with near-infrared spectroscopy and long term cardiovascular outcome in patients undergoing coronary angiography [ATHEROREMO study]. European Heart Journal, 2017, 38, .	2.2	0
103	P3653Evolution of renal function after acute coronary syndrome and prognostic impact of serial renal assessments in patients with normal-to-moderately reduced glomerular filtration rates: BIOMArCS study. European Heart Journal, 2017, 38, .	2.2	0
104	In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. Netherlands Heart Journal, 2017, 25, 634-642.	0.8	6
105	P3648Detailed temporal patterns of high-sensitivity-cardiac troponin I and T during long-term follow-up after acute coronary syndrome. European Heart Journal, 2017, 38, .	2.2	0
106	Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial. Circulation, 2016, 134, 984-986.	1.6	2
107	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. International Journal of Cardiology, 2016, 221, 682-687.	1.7	1
108	Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). Atherosclerosis, 2016, 254, 20-27.	0.8	10

7

#	Article	IF	CITATIONS
109	A simple risk chart for initial risk assessment of 30-day mortality in patients with cardiogenic shock from ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 101-107.	1.0	25
110	PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis, 2016, 248, 117-122.	0.8	137
111	Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease. International Journal of Cardiology, 2016, 202, 246-251.	1.7	16
112	Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound. PLoS ONE, 2015, 10, e0141093.	2.5	14
113	Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis, 2015, 243, 560-566.	0.8	120
114	High-sensitive troponin-T in adult congenital heart disease. International Journal of Cardiology, 2015, 184, 405-411.	1.7	28
115	Evaluation of 42 cytokines, chemokines and growth factors for prediction of cardiovascular outcome in patients with coronary artery disease. International Journal of Cardiology, 2015, 184, 724-727.	1.7	1
116	Tools and Techniques $\hat{a}$ €" Statistical: A brief non-statistician $\hat{a}$ €™s guide for choosing the appropriate regression analysis, with special attention to correlated data and repeated measurements. EuroIntervention, 2015, 11, 957-962.	3.2	4
117	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: Results from the ATHEROREMO-IVUS study. International Journal of Cardiology, 2014, 177, 847-853.	1.7	16
118	Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). American Journal of Cardiology, 2014, 114, 1497-1503.	1.6	44
119	Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. Atherosclerosis, 2014, 237, 84-91.	0.8	46
120	Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study. Atherosclerosis, 2014, 236, 18-24.	0.8	35
121	Tools and Techniques - Statistics: Analysis of continuous data using the t-test and ANOVA. EuroIntervention, 2013, 9, 765-767.	3.2	2
122	Lipoprotein(a), Interleukinâ€10, Câ€Reactive Protein, and 8‥ear Outcome After Percutaneous Coronary Intervention. Clinical Cardiology, 2012, 35, 482-489.	1.8	33
123	Distribution of echocardiographic parameters and their associations with cardiovascular risk factors in the Rotterdam Study. European Journal of Epidemiology, 2010, 25, 481-490.	5.7	21
124	Haplotypes of the <i>NR4A2/NURR1 </i> gene and cardiovascular disease: The Rotterdam Study. Human Mutation, 2009, 30, 417-423.	2.5	13
125	Echocardiographic parameters and all-cause mortality: The Rotterdam Study. International Journal of Cardiology, 2009, 133, 198-204.	1.7	40
126	Plasma Concentration of Heat Shock Protein 27 and Risk of Cardiovascular Disease: A Prospective, Nested Case-Control Study. Clinical Chemistry, 2008, 54, 139-146.	3.2	38

#	Article	IF	CITATIONS
127	The Female Advantage in Cardiovascular Disease: Do Vascular Beds Contribute Equally?. American Journal of Epidemiology, 2007, 166, 403-412.	3.4	82
128	Lipoprotein-associated phospholipase A2 and coronary calcification. Atherosclerosis, 2007, 191, 377-383.	0.8	29
129	Usefulness of Combining Complement Factor H and C-Reactive Protein Genetic Profiles for Predicting Myocardial Infarction (from the Rotterdam Study). American Journal of Cardiology, 2007, 100, 646-648.	1.6	10
130	Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study. Thrombosis and Haemostasis, 2007, 97, 288-95.	3.4	5
131	C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. European Heart Journal, 2006, 27, 1331-1337.	2.2	81
132	A Common Polymorphism in the Complement Factor H Gene Is Associated With Increased Risk of Myocardial Infarction. Journal of the American College of Cardiology, 2006, 47, 1568-1575.	2.8	83
133	C-reactive protein and risk of heart failure. The Rotterdam Study. American Heart Journal, 2006, 152, 514-520.	2.7	102
134	Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 631-636.	2.4	60
135	Spatial QRS-T angle predicts cardiac death in a general population. European Heart Journal, 2003, 24, 1357-1364.	2.2	226